The COVID-19 pandemic made 'mRNA vaccine' a household term. Now, Indian researchers are channelling that same technology into a new frontier: personalised medicine that could one day train a patient's own body to fight cancer.
Beyond the Pandemic: What is Personalised mRNA?
Messenger RNA (mRNA) technology
works by giving our cells a temporary set of instructions. For COVID-19 vaccines, this meant teaching cells to create a harmless piece of the virus, prompting an immune response. The next evolution of this technology is far more ambitious and individualised. Personalised mRNA therapy, particularly for cancer, isn't about preventing a disease in the general population; it's about treating one that already exists in a single person. The process involves sequencing a patient's tumour to identify its unique genetic mutations. These mutations create abnormal proteins called 'neoantigens'. An mRNA vaccine is then custom-designed to carry instructions for these specific neoantigens, effectively teaching the patient's immune system to recognise and attack only the cancer cells, leaving healthy cells unharmed.
PopVax and the 'RNA Foundry'
At the forefront of this effort in India is PopVax, a Hyderabad-based biotechnology startup. The company recently launched its 'RNA Foundry', an integrated facility for the research, development, and manufacturing of personalised RNA medicines. This move is significant because it brings the entire complex process—from analysing a tumour's genetics to producing a tailor-made vaccine—under one roof. Founded in late 2021, PopVax combines artificial intelligence (AI) and machine learning with molecular biology. Its AI platform analyses a tumour's genetic data to predict which neoantigens will trigger the most effective immune response. The company aims to produce a personalised vaccine candidate within eight to ten weeks of receiving a patient's tumour data.
From 'Pharmacy of the World' to Biotech Innovator
India is globally recognised as the 'pharmacy of the world' for its massive capacity to produce affordable generic drugs. However, the development of personalised mRNA therapies signals a pivotal shift. Instead of replicating existing medicines, companies like PopVax are focused on creating entirely new, high-value treatments from scratch. This emerging field represents a move up the value chain, from mass manufacturing to bespoke, technology-driven innovation. The work being done at PopVax and other Indian research institutes is crucial for building a domestic ecosystem for advanced therapies, reducing reliance on foreign technology and potentially making these futuristic treatments more accessible in the long run. PopVax itself has a stated mission to not only compete with but 'leapfrog' research in traditional biotech hubs like San Francisco and Boston.
The Road Ahead: Challenges and Potential
Despite the immense promise, personalised mRNA cancer vaccines are still in the early stages of development and are not yet routinely available in India or globally. The technology is experimental, and its effectiveness must be proven through rigorous clinical trials. Major challenges remain, including the high cost of development, navigating complex regulatory approvals, and scaling up manufacturing, even for individualised doses. The process is inherently complex, requiring sophisticated capabilities in genomics, bioinformatics, and biomanufacturing. PopVax plans to make its treatments available initially through compassionate-use pathways for a small number of patients, which will provide early data to guide future, larger trials. While its COVID-19 vaccine candidate has entered human trials in Australia, its cancer vaccines have not yet been administered to patients.
